Table 2 Outcomes of Subgroup Analysis of SBP
Subgroup | Number | MD 95CI | P | I2 | Subgroup | Number | MD 95CI | P | I2 |
|---|---|---|---|---|---|---|---|---|---|
Age (y) | 0.46 | 0 | ACEI /ARB (%) | 0.30 | 5 | ||||
 ≥ 70 | 3 | − 1.30 (− 2.10, − 0.49) |  ≥ 80 | 8 | − 1.23 (− 1.77, − 0.70) | ||||
 < 70 | 13 | − 1.93 (− 3.40, − 0.45) |  < 80 | 7 | − 2.85 (− 5.91, 0.20) | ||||
BMI (kg/m2) | 0.59 | 0 | β-block (%) | 0.55 | 0 | ||||
 ≥ 28 | 13 | − 1.63 (− 2.80, − 0.46) |  ≥ 80 | 10 | − 1.52 (− 2.83, − 0.21) | ||||
 < 28 | 3 | − 2.38 (− 4.84, 0.08) |  < 80 | 4 | − 2.26 (− 4.27, − 0.24) | ||||
Control | 0.83 | 0 | MRA (%) | 0.10 | 63.3 | ||||
Placebo | 13 | − 1.70 (− 2.87, − 0.53) |  ≥ 50 | 6 | − 0.85 (− 2.39, 0.69) | ||||
Other drugs | 4 | − 2.00 (− 4.39, 0.39) |  < 50 | 8 | − 2.97 (− 4.97, − 0.98) | ||||
Time (weeks) | 0.23 | 31.7 | Diuretic (%) | 0.22 | 33.3 | ||||
 > 12 | 8 | − 1.25 (− 2.05, − 0.46) |  ≥ 80 | 5 | − 1.51 (− 2.38, − 0.64) | ||||
 ≤ 12 | 9 | − 3.22 (− 6.40, − 0.04) |  < 80 | 8 | − 2.79 (− 4.66, − 0.93) | ||||
Number | 0.07 | 69.9 | â–³NT-proBNP (pg/ml) | 0.18 | 43.7 | ||||
 ≥ 100 | 10 | − 1.23 (− 1.96, − 0.51) |  ≥ 200 | 4 | − 4.80 (− 10.05, 0.44) | ||||
 < 100 | 7 | − 4.53 (− 7.95, − 1.10) |  < 200 | 7 | − 1.17 (− 2.20, − 0.13) | ||||
Diabetes | 0.33 | 9.6 | â–³Weight (kg) | 0.92 | 0 | ||||
Yes | 8 | − 2.65 (− 4.68, − 0.63) |  ≥ 2 | 3 | − 1.03 (− 6.26, 4.20) | ||||
No matter with or without DM | 9 | − 1.46 (− 2.71, − 0.21) |  < 2 | 8 | − 1.31 (− 1.84, − 0.79) | ||||
Hypertension (%) | 0.66 | 0 | â–³HbA1c (%) | 0.12 | 58.0 | ||||
 ≥ 80 | 4 | − 1.26 (− 2.06, − 0.45) |  ≥ 0.3 | 6 | − 3.95 (− 7.67, − 0.23) | ||||
 < 80 | 6 | − 1.63 (− 3.08, − 0.18) |  < 0.3 | 5 | − 0.94 (− 1.82, − 0.05) |